Close Menu

News Briefs

Premium

Cerenis Therapeutics Licenses HDL Therapy IP from Montreal Heart Institute

Cerenis Therapeutics said this week that it has licensed intellectual property from the Montreal Heart Institute Research Centre supporting the development of a drug for aortic valve stenosis based on high-density lipoprotein therapy.

The technology is based on the findings of Jean-Claude Tardif of MHIRC.

Cerenis, which has offices in Toulouse, France, and Ann Arbor, Mich., develops HDL-related compounds for treating cardiovascular and metabolic diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.